Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis' lead product HER-096, is an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. We are excited about the prospect to demonstrate blood brain barrier penetration by HER-096 in humans in 2023.